Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

981 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Current status of mammalian target of rapamycin inhibitors in lung cancer.
Gómez-Martín C, Rubio-Viqueira B, Hidalgo M. Gómez-Martín C, et al. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S13-8. doi: 10.3816/clc.2005.s.003. Clin Lung Cancer. 2005. PMID: 16159415 Review.
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C. Mueller MT, et al. Gastroenterology. 2009 Sep;137(3):1102-13. doi: 10.1053/j.gastro.2009.05.053. Epub 2009 Jun 6. Gastroenterology. 2009. PMID: 19501590
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Weekes CD, et al. Neoplasia. 2012 Aug;14(8):690-701. doi: 10.1593/neo.111810. Neoplasia. 2012. PMID: 22952422 Free PMC article.
The inverted pyramid of biomarker-driven trials.
Garrido-Laguna I, Hidalgo M, Kurzrock R. Garrido-Laguna I, et al. Nat Rev Clin Oncol. 2011 Aug 2;8(9):562-6. doi: 10.1038/nrclinonc.2011.113. Nat Rev Clin Oncol. 2011. PMID: 21808269 Review.
Development of the epidermal growth factor receptor inhibitor OSI-774.
Grünwald V, Hidalgo M. Grünwald V, et al. Semin Oncol. 2003 Jun;30(3 Suppl 6):23-31. doi: 10.1016/s0093-7754(03)70022-0. Semin Oncol. 2003. PMID: 12802792 Review.
New targets for cancer chemotherapy.
Murgo AJ, Dancey J, Eckhardt SG, Hidalgo M, Arbuck SG, Zerivitz K, Blaylock BA. Murgo AJ, et al. Cancer Chemother Biol Response Modif. 2002;20:239-72. Cancer Chemother Biol Response Modif. 2002. PMID: 12703208 No abstract available.
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK. Patnaik A, et al. Clin Cancer Res. 2006 Dec 15;12(24):7406-13. doi: 10.1158/1078-0432.CCR-06-1886. Clin Cancer Res. 2006. PMID: 17189413 Clinical Trial.
EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were treated continuously with erlotinib at doses of 100, 125, and 150 mg/d orally along with fixed i.v. doses of paclitaxel 225 mg/m(2) and carboplatin AUC 6 mg x min/mL, both on day 1 every 3 weeks. ...CONCLU …
EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were treated continuously with erlotinib at doses of 100, 125, and 150 mg/d o …
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK. Hidalgo M, et al. Clin Cancer Res. 2006 Oct 1;12(19):5755-63. doi: 10.1158/1078-0432.CCR-06-0118. Clin Cancer Res. 2006. PMID: 17020981 Clinical Trial.
The maximum tolerated dose was 15 mg/m(2)/d for patients with extensive prior treatment because, in the 19 mg/m(2)/d cohort, two patients had dose-limiting toxicities (one with grade 3 vomiting, diarrhea, and asthenia and one with elevated transaminases) and three p …
The maximum tolerated dose was 15 mg/m(2)/d for patients with extensive prior treatment because, in the 19 mg/m(2)/d cohort, t …
981 results
Jump to page
Feedback